### Check for updates

### OPEN ACCESS

EDITED BY Xiaohua Jiang, Tongji University, China

REVIEWED BY Chengyu Liu, Peking Union Medical College Hospital (CAMS), China Susana S. Couto Irving, Consultant, London, United Kingdom

\*CORRESPONDENCE Hanping Shi Shihp@ccmu.edu.cn

<sup>†</sup>These authors have contributed equally to this work and share first authorship

RECEIVED 11 November 2023 ACCEPTED 09 April 2024 PUBLISHED 25 April 2024

#### CITATION

Zhao H, Liu C, Ruan G, Zheng X, Chen Y, Lin S, Liu X, Shi J, Li X, Li S and Shi H (2024) The quality of life impacting factors in malnourished patients with gastric cancer. *Front. Oncol.* 14:1336859. doi: 10.3389/fonc.2024.1336859

#### COPYRIGHT

© 2024 Zhao, Liu, Ruan, Zheng, Chen, Lin, Liu, Shi, Li, Li and Shi. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

# The quality of life impacting factors in malnourished patients with gastric cancer

Hong Zhao<sup>1,2,3†</sup>, Chenan Liu<sup>1,2,3†</sup>, Guotian Ruan<sup>1,2,3†</sup>, Xin Zheng<sup>1,2,3</sup>, Yue Chen<sup>1,2,3</sup>, Shiqi Lin<sup>1,2,3</sup>, Xiaoyue Liu<sup>1,2,3</sup>, Jinyu Shi<sup>1,2,3</sup>, Xiangrui Li<sup>1,2,3</sup>, Shuqun Li<sup>1,2,3</sup> and Hanping Shi<sup>1,2,3</sup>\*

<sup>1</sup>Department of Gastrointestinal Surgery/Department of Clinical Nutrition, Beijing Shijitan Hospital, Capital Medical University, Beijing, China, <sup>2</sup>Key Laboratory of Cancer FSMP for State Market Regulation, Beijing, China, <sup>3</sup>National Clinical Research Center for Geriatric Diseases, Xuanwu Hospital, Capital Medical University, Beijing, China

**Introduction:** Malnutrition is prevalent among individuals with gastric cancer and notably decreases their quality of life (QOL). However, the factors impacting QOL are yet to be clearly defined. This study aimed to identify essential factors impacting QOL in malnourished patients suffering from gastric cancer.

**Methods:** By using the Patient-Generated Subjective Global Assessment (PG-SGA) to assess the nutritional status ( $\geq$ 4 defined malnutrition) of hospitalized cancer patients, 4,586 gastric cancer patients were ultimately defined as malnourished. Spearman method was used to calculate the relationship between clinical features and the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30). Then, univariate and multivariate logistic regression were used to observe which factors affected QOL, and subgroup analysis was performed in young and old population respectively. In addition, we used univariate and multivariate logistic regression to explore whether and how self-reported frequent symptoms in the last 2 weeks of the PG-SGA score affected QOL.

**Results:** In multivariate logistic regression analysis of clinical features of patients with malnourished gastric cancer, women, stage II, stage IV, WL had an independent correlation with a low global QOL scores. However, BMI, secondary education, higher education, surgery, chemotherapy, HGS had an independent correlation with a high global QOL scores. In multivariate logistic regression analysis of symptoms in self-reported PG-SGA scores in patients with malnourished gastric cancer, having no problem eating had an independent correlation with a high global QOL scores. However, they have no appetite, nausea, vomiting, constipation and pain had an independent correlation with a lower global QOL scores. The p values of the above statistical results are both < 0.05.

**Conclusion:** This study demonstrates that QOL in malnourished patients with gastric cancer is determined by female sex, stage II, stage IV, BMI, secondary and higher education or above, surgery, chemotherapy, WL, and HGS. Patients' self-

reported symptoms of nearly 2 weeks, obtained by using PG-SGA, are also further predictive of malnourished gastric cancer patients. Detecting preliminary indicators of low QOL could aid in identifying patients who might benefit from an early referral to palliative care and assisted nursing.

KEYWORDS

gastric cancer, quality of life, malnourishment, PG-SGA, young and old

# Introduction

Despite variations in incidence and mortality rates across different regions, gastric cancer is the fifth most commonly detected cancer worldwide and the fourth most common cause of death due to cancer (1). In China, it is the second leading cause of death related to cancer (2). The incidence and progression of this disease is determined by an interplay of environmental and genetic factors, indicating that gastric cancer is multifactorial in nature (3). Currently, the management of gastric cancer is far from optimal, given that patients, irrespective of their disease subtype, generally receive uniform treatment (4). Recently, there has been a shift in discussion and decision-making about cancer care, especially when considering patient selection, from a variety of clinical outcomes to patient-centered outcomes such as QOL (5). There has also been a significant evolution in palliative care and treatment approaches, where the objective is to unify life-extending treatments with patient QOL (4, 6-11). Although new therapies and technologies can improve treatment outcomes in cancer patients, it is of equal importance to maintain physical and emotional health by assessing QOL (12, 13), which is negatively affected by cancer (14). Patients with late-stage or uncontrollable gastric cancer constantly experience malnutrition, which affects their QOL, increases the chemotherapy toxicity and reduces the overall survival rate (15, 16). Despite the widespread prevalence of gastric cancer worldwide, our knowledge about its effect on QOL is still limited (17). The goal of this research is to assess the factors impacting the QOL of malnourished patients with gastric cancer. The findings of this study will enhance care strategies and management of patients, and offer vital references for future clinical practice and research.

# Materials and methods

### Study population

The INSCOC is a nationwide survey exploring the link between nutritional health and clinical results in patients suffering from malignant tumors. This project was both conceived and put into action by the Tumor Nutrition and Support Professional Committee within the Chinese Cancer Society. Ethical approval for the study was granted by the reviewing bodies of all participating institutions, with all participants giving their informed written consent. The criteria for participation in this study were as follows:

- 1. Individuals aged 18 to 90 years with full mental capacity, no communication issues, and capable of participating in the necessary examinations.
- 2. Histological diagnosis of gastric cancer.
- 3. Experienced multiple hospitalizations for the same condition.
- 4. Comprehensive documentation of medical history and any subsequent data.
- 5. Able to voluntarily participate.

The exclusion criteria were as follows:

- 1. Patients with HIV/AIDS or organ transplant recipients.
- 2. Patients in critical condition or difficult to evaluate.
- 3. Patients who refuse or do not cooperate with the survey questionnaire.

## Procedure and assessment

We use Investigation on Nutrition Status and Clinical Outcome of Common Cancers (INSCOC) data screened 5,845 eligible adult patients with gastric cancer from 26 provinces and municipalities in China between 2012 and 2022. Professional staff used a standardized questionnaire and professional measurement methods to collect information on sex, age, TNM stage, body mass index (BMI) (18), the rate of weight loss over one month (WL), hand grip strength (HGS),occupation, education level, residence, and treatment within the initial 48 hours of hospital admission. Missing data is interpolated using R software (Supplementary Figure 1). By Asian standards, HGS is classified as low grip strength (HGS<18 for Female; HGS<28 for Male) and high grip strength (HGS>18 for Female; HGS>28 for Male) (19).

10.3389/fonc.2024.1336859

Occupations are divided into mental work, manual work and retired or other. Mental work includes professional or managerial personnel, civil servants, teachers, career and enterprise staff. Manual work includes farmers and workers. The level of education is divided into higher education (college, bachelor's, master's and above), secondary education (middle and high school) or no education and primary education. Patient-Generated Subjective Global Assessment (PG-SGA) and the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) (20) are obtained by the investigators in the form of filling in questionnaires after the patients understand the questions and explain the questions. In this way, the errors caused by the patients' unclear understanding can be avoided to the maximum extent. The PG-SGA score is recognized by the American Society for Parenteral and Enteral Nutrition (ASPEN) as the benchmark nutritional assessment tool for cancer patients. The PG-SGA score is composed of patient self-assessment and a comprehensive assessment by the health care provider and is not a short form of nutritional risk screening. The PGSGA score is 0-1 (no intervention is required at this time, and routine follow-up and evaluation are maintained during treatment). The PG-SGA score is 2-3 (patient or patient family education by a dietitian, nurse, or physician, and medical intervention may be performed based on the presence of symptoms and the results of laboratory tests). The PG-SGA score of 4-8 (intervention by a dietitian and, depending on the severity of symptoms, in conjunction with a physician and caregiver). The PG-SGA score≥9 (urgent need for symptom improvement and/or concurrent nutritional intervention). In this study, PG-SGA≥4 was defined as malnutrition, and the higher the score, the more severe the malnutrition, on the contrary, the lower the score, the better the nutritional status. QOL was assessed using the EORTC QLQC30, which evaluates 5 functional scores (physical function, role function, emotional function, congnitive function, social function), global health, 3 symptom scales (fatigue, nausea and vomiting, pain), 6 individual measures (dyspnea, sleep disturbance, appetite loss, constipation, diarrhea, financial difficulties). The computation of each domain's summary QOL score (0-100) adhered to the EORTC QLQ-C30 formulas. Higher scores on the functional and global health status scales indicate improved functioning. Conversely, Symptom scales and individual measurement items use negative scores, with higher scores indicating greater intensity. The total score of the QOL is added by each functional score, then added to 800 minus 3 symptom scores and 5 individual measures (except financial difficulties), and finally 13 (21).

# Statistical analysis

We employed a multiple imputation chain-equation method to impute missing data, assuming that the missingness was random. Predictive mean matching was used to impute missing continuous variables, while a logistic regression model was used for imputing missing binary variables. Through 100 iterations, we generated five imputed datasets and analyzed each separately. Finally, we combined the results using Rubin's method. The data is presented as a simple percentage or median interquartile range (IQR). The correlation between clinical features of patients with malnourished gastric cancer and EORTC QLQ-C30 was calculated by the spearman method. The greater the absolute value of the correlation coefficient calculated by the spearman method, the stronger the correlation was. Then the OR is calculated by univariable and multivariable logistic regression. The OR>1 indicates that it is a predictor of outcome events (low global QOL scores, low physical function scores, high fatigue scores, high appetite loss scores). The OR<1 indicates that it is a predictor of outcome events (high global QOL scores, high physical function scores, low fatigue scores, low appetite loss scores). The above scores are compared with the average. If in univariate and multivariate logistic regression, p values are both <0.05, indicating that this factor can independently affect outcome events. R software, version 4.3.0, was used for all analytical procedures.

# Results

## **Baseline characteristics**

The baseline characteristics of 5845 gastric cancer patients were shown in supplementary Table 1, of which 4586 (78.5%) were malnourished. In Table 1, we observed the baseline characteristics of 4586 malnourished patients with gastric cancer, 3149 men (68.7%) and 1437 women (31.3%). the median age was 60 years old, IQR (52.00, 67.00). Of the total number of patients, 546 patients in stage I (11.9%); 884 patients in stage II (19.3%); 1813 patients in stage III (39.5%), and 1,343 patients in stage IV (29.3%). The median BMI was 20.57 (IQR 18.44, 22.96). Less than half of patients were treated with surgery, chemotherapy or radiotherapy. More than half of the patients with gastric cancer experienced WL (69.1%). There were 2358 (51.4%) people with low HGS and 2228 (48.6%) people with high HGS. 1720 (37.5%) of the study population had primary education or no education, 2259 (49.3%) had secondary education, and 607 (13.2%) had higher education. The proportion of patients living in urban and rural areas is similar.

# Relationship between clinical and nutritional determinants and EORTC QLQC30 scores

Female ( $\rho$ -0.11), age ( $\rho$ -0.05), tumor stage ( $\rho$ -0.08) and WL ( $\rho$ -0.1) were negatively correlated with the global QOL score. BMI ( $\rho$ 0.16), surgery ( $\rho$ 0.04), chemotherapy ( $\rho$ 0.07), HGS ( $\rho$ 0.24) and education ( $\rho$ 0.06) were positively correlated with the global score of QOL (Tables 2, 3).

TABLE 1 Characteristics of patients with malnourished gastric cancer.

Characteristics	Sample size (n=4586)
Sex	Sumple Size (II-4300)
Male	3149 ( 68.7)
Female	1437 ( 31.3)
Age TNM stage	60.00 [52.00, 67.00]
I	546 ( 11 0)
	546 ( 11.9)
	884 ( 19.3)
III	1813 ( 39.5)
IV	1343 ( 29.3)
BMI	20.57 [18.44, 22.96]
Surgery	
No	2639 ( 57.5)
Yes	1947 ( 42.5)
Chemotherapy	
No	2554 ( 55.7)
Yes	2032 ( 44.3)
Radiotherapy	
No	4477 ( 97.6)
Yes	109 ( 2.4)
WL%	
≤0	1418 ( 30.9)
0~5	1383 ( 30.2)
5~10	1211 ( 26.4)
>10	574 ( 12.5)
HGS	
<18 for women or <28 for men	2358 ( 51.4)
≥18 for women or≥28 for men	2228 ( 48.6)
Education	
Primary education or never attended school	1720 ( 37.5)
Secondary education	2259 ( 49.3)
Higher education	607 ( 13.2)
Occupation	
Mental work	495 ( 10.8)
Manual work	1896 ( 41.3)
Retired or other	2195 ( 47.9)
Residence	
Urban	2188 ( 47.7)
Rural	2398 ( 52.3)

The summary statistics present N% for categorical variables and median [IQR] deviation for continuous variables.

# Clinical and nutritional determinants related to poorer global QOL scores

The global QOL scores was segmented based on the mean score (82.83) in the univariable and multivariate logistic regression analysis (Figures 1A, B). Female sex (OR, 1.57; 95% CI, 1.37-1.81; P<0.001), stage II (OR, 1.28; 95% CI, 1.01-1.63; P =0.043), stage IV (OR, 1.83; 95% CI, 1.45-2.32; P<0.001) and WL (WL 5-10%: OR, 1.31; 95% CI, 1.10-1.55; P =0.002; WL>10%: OR, 1.55; 95% CI, 1.24-1.92; P<0.001) were an independent predictor of a lower global QOL scores (<82.83). BMI (OR, 0.95; 95% CI, 0.93-0.97; P<0.001), secondary education (OR, 0.81; 95% CI, 0.70-0.94; P =0.006), higher education (OR, 0.78; 95% CI, 0.61-1.00; P =0.048), surgery (OR, 0.59; CI, 0.48-0.72; P < 0.001), chemotherapy (OR, 0.57; 95% CI, 0.47-0.68;P<0.001) and high HGS (OR, 0.53; 95% CI, 0.46-0.60; P< 0.001) were an independent predictor of higher global QOL scores (≥82.83). The study population was divided into young group (<65) and elderly group ( $\geq 65$ ), and subgroup analysis was performed. We found that in the elderly population, the age (OR, 1.03; 95% CI, 1.01-1.05; P =0.008) was an independent predictor of low global QOL scores, and other results were similar to those of the total population analysis (Supplementary Table 3B). In the young age group, the results obtained are similar to the results of the general population analysis (Supplementary Table 3A).

# Parameters related to clinical and nutritional aspects linked to diminished physical function

Figures 2A, B show the physical function in The EORTC QLQC30 score divided by an average score (78.67). In multivariate logistic regression analysis, women (OR, 1.53; 95% CI, 1.32-1.77; P< 0.001), age (OR, 1.01; 95% CI, 1.01-1.02; P < 0.001), stage II (OR, 1.38; 95% CI, 1.07-1.78; P =0.013), stage IV (OR, 1.80; 95% CI, 1.40-2.31; P <0.001) and WL >10 (OR, 1.55; 95% CI, 1.24-1.93; P <0.001) were associated with poor physical function (< 78.67) of independent predictors. BMI (OR, 0.95; 95% CI, 0.93-0.97; P <0.001), secondary school (OR, 0.78; 95% CI, 0.66-0.91; p=0.002), surgery (OR, 0.55; 95% CI, 0.44-0.68; p<0.001), chemotherapy (OR, 0.57; 95% CI, 0.47-0.70; p<0.001) and high HGS(OR, 0.46; 95% CI, 0.40-0.53; p<0.001) were an independent predictor of better physical function (≥78.67). In a subgroup analysis of age, in the younger age group, results were obtained that were similar to the general population (Supplementary Table 4A). In the elderly population, the age (OR, 1.06; 95% CI, 1.04-1.09; p<0.001) became an independent predictor of lower physical function scores (Supplementary Table 4B).

# Parameters related to clinical and nutritional aspects linked to increased fatigue

Figures 3A, B show the fatigue in The EORTC QLQC30 score divided by an average score (24.15). In multivariate logistic

TABLE 2 Relationship between clinical and nutritional determinants and EORTC QLQC30 scores.

Varible	No.of patients	Physical function		Role function		Emotional function		Cognitive function		Social function		Global health		Global QOL	
Sex		ρ	Р	ρ	Р	ρ	Р	ρ	Р	ρ	Р	ρ	Р	ρ	Р
Men, Women	4586	-0.1	< 0.001	-0.08	< 0.001	-0.08	< 0.001	-0.06	< 0.001	-0.06	< 0.001	-0.07	< 0.001	-0.11	< 0.001
Age															
60.00 [52.00, 67.00]	4586	-0.12	< 0.001	-0.05	< 0.001	0.07	< 0.001	-0.09	< 0.001	-0.01	0.185	-0.04	0.001	-0.05	< 0.001
Tumor stage															
I, II, III, IV	4586	-0.1	< 0.001	-0.12	< 0.001	-0.03	0.21	-0.04	0.033	-0.06	< 0.001	-0.06	< 0.001	-0.08	< 0.001
BMI															
20.57 [18.44, 22.96]	4586	0.19	< 0.001	0.14	< 0.001	0.06	< 0.001	0.1	< 0.001	0.12	< 0.001	0.15	< 0.001	0.16	< 0.001
Surgery															
No or Yes	4586	0.13	< 0.001	0.14	< 0.001	-0.04	0.001	0.06	0.004	0.08	< 0.001	0.01	0.731	0.04	0.015
Chemotherapy															
No or Yes	4586	0	< 0.001	-0.04	0.602	0.08	< 0.001	0.03	0.002	0	0.247	0.08	< 0.001	0.07	< 0.001
Radiotherapy															
No or Yes	4586	-0.01	0.69	-0.01	0.888	0	0.736	0	0.596	-0.01	0.358	-0.02	0.213	-0.02	0.549
WL															
≤0%, 0-5%, 5%-10%, >10%	4586	-0.08	< 0.001	-0.08	< 0.001	-0.04	< 0.001	-0.02	0.091	-0.05	< 0.001	-0.08	< 0.001	-0.1	< 0.001
HGS															
<18 for women or <28 for men, ≥18 for women or≥28 for men	4586	0.28	<0.001	0.2	<0.001	0.09	<0.001	0.18	<0.001	0.19	<0.001	0.19	< 0.001	0.24	<0.001
Education															
Primary education or never attended school, Secondary education, Higher education	4586	0.06	0.014	0.02	0.657	0.03	0.076	0.1	<0.001	0.07	<0.001	0.07	<0.001	0.06	0.004
Occupation		·						·							
Mental work, Manual work, Retired or other	4586	-0.07	<0.001	-0.07	<0.001	0.04	0.028	-0.02	0.018	0.02	0.165	-0.01	0.649	-0.01	0.359
Residence															
Urban, Rural	4586	0.04	0.001	0.04	0.001	-0.04	0.066	0	0.716	-0.03	0.032	-0.07	< 0.001	-0.01	0.339

Varible	No.of patients	Fatigue		Nausea and vomiting		Pain		Dyspnea		Sleep disturbance		Appetite loss		Constipation		Diarrhea		Financial difficulties	
Sex		ρ	Р	ρ	Р	ρ	Р	ρ	Р	ρ	Р	ρ	Р	ρ	Р	ρ	Р	ρ	Р
Men, Women	4586	0.08	< 0.001	0.09	< 0.001	0.06	< 0.001	0.02	0.108	0.09	< 0.001	0.09	< 0.001	0.01	0.308	0.04	0.001	0.03	0.014
Age																			
60.00 [52.00, 67.00]	4586	0.06	<0.001	-0.03	0.205	-0.04	0.161	0.07	<0.001	-0.01	0.628	0.05	<0.001	0.04	0.018	-0.02	0.578	-0.06	0.002
Tumor stage																			
I, II, III, IV	4586	0.08	< 0.001	0.09	< 0.001	0.02	0.165	0.03	0.027	0.03	0.225	0.08	< 0.001	0.06	< 0.001	0	0.678	-0.01	0.188
BMI																			
20.57 [18.44, 22.96]	4586	-0.16	<0.001	-0.1	<0.001	-0.03	0.037	-0.06	0.001	-0.1	<0.001	-0.1	< 0.001	-0.09	< 0.001	-0.05	<0.001	-0.1	< 0.001
Surgery																			
No or Yes	4586	-0.06	0.001	-0.01	0.334	0.15	< 0.001	-0.02	0.217	-0.01	0.803	-0.04	0.118	-0.04	0.008	-0.03	0.043	0.03	0.005
Chemotherapy																			
No or Yes	4586	-0.03	< 0.001	-0.04	0.001	-0.2	< 0.001	-0.04	0.002	-0.05	< 0.001	-0.04	< 0.001	-0.03	0.012	0.01	0.819	-0.07	< 0.001
Radiotherapy																			
No or Yes	4586	0	0.71	0.01	0.279	0	0.62	0.02	0.267	0.01	0.683	0.03	0.109	0.02	0.132	0.01	0.545	0.03	0.085
WL																			
≤0%, 0-5%, 5%- 10%, >10%	4586	0.11	<0.001	0.07	< 0.001	0.02	0.019	0.03	0.027	0.07	<0.001	0.08	< 0.001	0.07	< 0.001	0.03	0.029	0.04	0.006
HGS																			
<18 for women or <28 for men, ≥18 for women or≥28 for men	4586	-0.22	<0.001	-0.08	<0.001	-0.09	<0.001	-0.12	<0.001	-0.11	<0.001	-0.13	<0.001	-0.08	<0.001	-0.06	<0.001	-0.12	<0.001
Education																			
Primary education or never attended school, Secondary education, Higher education	4586	-0.02	0.718	-0.03	0.181	-0.04	0.095	-0.01	0.574	-0.04	0.035	-0.04	0.01	0	0.954	0.01	0.387	-0.17	<0.001

Zhao et al.

(Continued)

001

00

regression analysis, women (OR, 1.40; 95% CI, 1.22-1.61; p<0.001),
stage IV (OR, 1.46; 95% CI, 1.16-1.83; P =0.001) and WL of 5-10
(OR, 1.33; 95% CI, 1.13-1.57; p<0.001), WL of >10 (OR, 1.70; 95%
CI, 1.37-2.10; p<0.001) were an independent predictor of higher
fatigue scores (≥24.15). BMI (OR, 0.95; 95% CI, 0.93-0.96; p<0.001),
surgery (OR, 0.73; 95% CI, 0.62-0.85; p<0.001), and high HGS (OR,
0.53; 95% CI, 0.47-0.61; p<0.001) were a low fatigue scores (<24.15)
of independent predictors. In subgroup analysis, in the elderly
population, the age (OR, 1.03; 95% CI, 1.01-1.05; p=0.007) was an
independent predictor of higher fatigue scores, and other
observations were similar (Supplementary Table 5B). Results were
observed in younger age groups similar to the general population
(Supplementary Table 5A).

# Parameters related to clinical and nutritional aspects linked to increased appetite loss

Figures 4A, B show that appetite loss in the EORTC QLQC30 score was divided by mean score (21.56). In multivariate logistic regression analysis, female (OR, 1.53; 95% CI, 1.34-1.75; p< 0.001), age (OR, 1.01; 95% CI, 1.00-1.01; p=0.005), stage IV (OR, 1.55; 95% CI, 1.24-1.95; P < 0.001), WL of 0-5 (OR, 1.32; 95% CI, 1.13-1.55; P<0.001), WL of 5-10 (OR, 1.29; 95% CI, 1.09-1.52; P =0.003) and WL >10 (OR, 1.43; 95% CI, 1.16-1.77; P < 0.001) were an independent predictor of higher appetite loss scores ( $\geq$ 21.56). BMI (OR, 0.97; 95% CI, 0.95-0.99; P =0.001), surgery (OR, 0.68; 95% CI, 0.56-0.84; P< 0.001), chemotherapy (OR, 0.79; 95% CI, 0.65-0.95; P =0.013) and high HGS (OR, 0.75; 95% CI, 0.66-0.85; P <0.001) were a lower appetite loss scores (< 21.56) of independent predictors. In the subgroup analysis of age, similar results were obtained in the older and younger groups, respectively (Supplementary Tables 6A, B).

# The relationship between PG-SGA symptoms and the global QOL scores

As part of the added value of PG-SGA, we also explored the relationship between self-reported symptoms and global QOL scores in the last 2 weeks. In multivariate logistic regression analysis, having no problem eating (OR, 0.59; 95% CI, 0.50-0.71; P < 0.001) was an independent predictor of high QOL scores. Having no appetite (OR, 2.19; 95% CI, 1.88-2.55; p< 0.001), nausea (OR, 1.61; 95% CI, 1.34-1.95; P<0.001), vomiting (OR, 2.22; 95% CI, 1.81-2.73; p<0.001), constipation (OR, 2.00; 95% CI, 1.62-2.48; P <0.001) and pain (OR, 1.32; 95% CI, 1.13-1.54; P <0.001) were an independent predictor of low QOL scores (Figure 5).

# Discussion

Our results suggest that women are independent predictors of lower global QOL scores, lower physical function scores, higher fatigue scores, and higher appetite loss scores, and that more

		<0.06		>0.00	
Financial difficulties		-0.09		0.17	
		0.183		0.001	
Diarrhea		0.01		-0.05	
		0.077		0.045	
Constipation		0.02		-0.02	
		0.688		0.702	
Appetite loss		-0.01		0.01	
		0.922		0.683	
Sleep disturbance		-0.01		0.02	
		0.171		0.017	
Dyspnea		0.01		-0.03	
		0.147		0.032	
Pain		-0.03		0.05	
		0.427		0.738	
Nausea and vomiting		-0.02		0	
		0.627		0.499	
Fatigue		-0.01		-0.01	
No.of patients		4586		4586	nt.
Varible	Occupation	Mental work, Manual work, Retired or other	Residence	Urban, Rural	p, correlation coefficient.

Frontiers in Oncology

**FABLE 3** Continued



(A) Clinical and Nutritional Parameters Related to Poor Global QOL average score (Below the Mean of <82.83) According to Univariable Logistic Regression Analysis. OR, odds ratio; CI, confidence interval; The summary statistics present N% for categorical variables and median [IQR] deviation for continuous variables. (B) Clinical and Nutritional Parameters Related to Poor Global QOL average score (Below the Mean of <82.83) According to Multivariable Logistic Regression Analysis. OR, odds ratio; CI, confidence interval; The summary statistics present N% for categorical variables and median [IQR] deviation for continuous variables.

attention should be paid to older patients when it comes to QOL in cancer patients. The symptoms of PG-SGA that occurred frequently in the last 2 weeks were also correlated with QOL scores.

Globally, gastric cancer continues to be a major contributor to cancer-related deaths, owing to its high mortality rate. This is largely because most diagnoses occur at later stages, when prognosis is often poor and treatment options are limited (22, 23). Alleviating symptoms, particularly malnourishment, and improving QOL should be a main objective of care (24). As far as we know, this is the first study to report an extensive examination of how the clinical aspects of nutrition impact the QOL of malnourished patients diagnosed with gastric cancer. Our results indicate that female patients may experience malnutrition more often than men. This is consistent with earlier studies, which also

							в						
haracteristics	aPhysical function average score (n=3013)	<physical (n="1573)&lt;/th" average="" function="" score=""><th></th><th></th><th>P-Value</th><th>OR(95%CI)</th><th>Characteristics</th><th>aPhysical function average score (n+3013)</th><th>«Physical function average score (n=1573)</th><th></th><th></th><th>P-Value</th><th>ORISE</th></physical>			P-Value	OR(95%CI)	Characteristics	aPhysical function average score (n+3013)	«Physical function average score (n=1573)			P-Value	ORISE
ex							Sex						
ale	2141 (71.1%)	1008 (64.1%)		1			Male	2141 (71.1%)	1008 (64, 1%)				
omalo	872 (28.9%)	565 (35.9%)			<0.001	1.38 (1.21-1.57)	Ferrain	872 (28.9%)	565 (35.9%)		<b>—</b>	+0.001	1.53(1.3
ge	59.00 (51.00. 66.00)	61.00 [53.00.69.00]			<0.001	1.02 (1.01-1.02)	Age						
NM stage	58.00 [51.00, 66.00]	61.00 (53.00, 69.00)		1	-0.001	1.02 (1.01-1.02)		59.00 (51.00. 66.00)	61.00 (53.00. 69.00)			-0.001	1.01 (1.0
nii ologo	390 (12.9%)	158 (9.9%)					TNM stage			[			
	582 (19.3%)	302 (19.2%)			0.025	1.30 (1.03-1.64)		390 (12.9%)	156 (8.9%)				
	1252 (41.6%)	561 (35.7%)				1.12 (0.91-1.30)		582 (19.3%)	302 (19.2%)			0.013	1.38 (1.0
	789 (25.2%)	554 (35.2%)			<0.001	1.76 (1.42-2.18)		1252 (41.6%)	561 (35.7%)		• · · ·		1.15 (0.9
M							ĸ	789 (25.2%)	554 (35.2%)				
	20.63 [18.86, 23.18]	19.82 [17.72, 22.32]			<0.001	0.91 (0.69-0.92)	BMI						
coupation								20.83 [18.86, 23.18]	19.82 [17.72, 22.32]			<0.001	0.95 (0.9
lental work	342 (11.4%)	153 (9.7%)					Occupation						
lanual work	1269 (42.1%)	627 (39.9%)	H	• · · · ·	0.361	1.10 (0.89-1.37)	Mental work	342 (11.4%)	153 (9.7%)				
efired or other	1402 (46.5%)	793 (50.4%)		<b>→</b> →→	0.028	1.26 (1.03-1.56)	Manual work	1209 (42.1%)	627 (39.9%)			0.885	0.98 (0.3
ducation							Batired or other	1402 (46.5%)	793 (50.4%)	- ' <del>   </del>	_		1.01 (0.7
rimary education or never attended school	1066 (35.4%)	654 (41.6%)					Education	1442 (44.574)	100 (00 4 10)			0.240	LUT BUT
econdary education	1561 (51.8%)	698 (44.4%)	H+			0.73 (0.64-0.83)	Primary education or never attended school	1066 (35.4%)	654 (41.6%)				
igher education	386 (12.8%)	221 (14%)			0.480	0.93 (0.77-1.13)	Secondary extagation	1581 (51.8%)	628 (44.4%)			0.002	0.78 (0.6
urgery							Higher education	395 (12,8%)	221 (14%)		_		0.91 (0.7
•	1667 (55%)	982 (62.4%)					Surgery	000 (12.0 /4)	221 (14-3)			0.406	0.01 (0.1
15	1356 (45%)	591 (37.6%)	H+		<0.001	0.74 (0.65-0.83)	No	1007 (00%)	982 (82.4%)				
hemotherapy							700 700	1356 (45%)	591 (37,6%)	H+1		<0.001	0.00
0	1632 (54 2%)	922 (58.6%)					Chemotherapy	1930 (4936)	001 (01.050)			40.001	0.50 (0.4
	1381 (45.8%)	651 (41.4%)	++-		0.004	0.83 (0.74-0.94)	No	1632 (54.2%)	922 (58.6%)				
adiotherapy o	2941 (97,826)	1536 (97.6%)					Yes	1381 (45,8%)	922 (36.0%) 651 (41.4%)	H+		-0.001	0.07.00.4
o 15	72 (2.4%)	1536 (97.6%) 37 (2.4%)			0.817	0.98 (0.66-1.47)	WL%	(201 (¥0.0%)	001 (41.450)			40.001	0.57 (0.4
15 A.%	72 (2.4%)	37 (2.4%)			0.807	0.98 (0.66-1.47)	10 NO.	973 (32.3%)	445 (28.3%)				
1	973 (32.3%)	445 (28.3%)					0.5	940 (31,2%)	443 (28.2%)			0.321	1.09 (0.9
5	940 (31,2%)	443 (28.2%)	_		0.712	1.03 (0.68-1.21)	5-10		443 (28.2%) 427 (27.1%)		_		1.13 (0.9
10	784 (26%)	427 (27.1%)				1.19 (1.01-1.40)	>10	784 (26%) 316 (10.5%)		- T		-0.001	
10	316 (10.5%)	258 (16.4%)				1.79 (1.46-2.18)	510	316 (10.5%)	258 (16.4%)			-10.001	1.55 (1.2
GS	,						<18 for women or <28 for men		1060 (67.4%)				
18 for women or <28 for men	1298 (43,1%)	1060 (67,4%)						1298 (43.1%)					
18 for women or µ28 for men	1715 (56.9%)	513 (32.6%)	H		<0.001	0.37 (0.32-0.42)	±18 for women or ±28 for men	1715 (56.9%)	513 (32.6%)	H		<0.001	0.46 (0.4
esidence							Residence						
tan	1394 (46.3%)	794 (50.5%)					Urban	1394 (46.3%)	794 (90.5%)				
ural	1619 (53.7%)	779 (49.5%)			0.007	0.84 (0.75-0.95)	Bural	1619 (53.7%)	779 (49.5%)	H+	1	0.530	0.95 (0.8

### FIGURE 2

(A) Clinical and Nutritional Parameters Related to Poor Physical function average score (Below the Mean of <78.67) According to Univariable Logistic Regression Analysis. OR, odds ratio; CI, confidence interval; The summary statistics present N% for categorical variables and median [IQR] deviation for continuous variables. (B) Clinical and Nutritional Parameters Related to Poor Physical function average score (Below the Mean of <78.67) According to Multivariable Logistic Regression Analysis. OR, odds ratio; CI, confidence interval; The summary statistics present N% for categorical variables and median [IQR] deviation for continuous variables.

haracteristics	<fatigue (n="2639)&lt;/th" average="" score=""><th>⊯Fatigue average score (n=1947)</th><th></th><th>P-Value</th><th>OR(95%CI)</th><th>B</th><th><fatigue (n="2639)&lt;/th" average="" score=""><th>≥Fatigue average score (n=1947)</th><th></th><th>P-Value</th><th>OR(95</th></fatigue></th></fatigue>	⊯Fatigue average score (n=1947)		P-Value	OR(95%CI)	B	<fatigue (n="2639)&lt;/th" average="" score=""><th>≥Fatigue average score (n=1947)</th><th></th><th>P-Value</th><th>OR(95</th></fatigue>	≥Fatigue average score (n=1947)		P-Value	OR(95
ex ale						Sex					
are emaie	1884 (71.4%)	1265 (65%) 682 (35%)		0.004							
	755 (28.6%)	682 (35%)		<0.001	1.35 (1.19-1.53)	Male	1884 (71.4%)	1265 (65%)			
ge	60.00 (52.00, 66.00)	60.00 [52.00, 67.00]		0.002	1.01 (1.00-1.01)	Female	755 (28.6%)	682 (35%)	<b>⊢</b> •−−1	<0.001	1.40 (1.2
NM stage	60.00 [52.00, 66.00]	60.00 [52.00, 67.00]		0.002	1.01 (1.00-1.01)	Age					
nim stage	345 (13.1%)	201 (10.3%)				- <u>-</u>					
	518 (19,6%)	366 (18.8%)		0.085	1.21 (0.97-1.51)		60.00 [52.00, 66.00]	60.00 [52.00, 67.00]	+	0.085	1.01 (1.0
	1082 (41%)	731 (37.5%)			1.16 (0.95-1.41)	TNM stage					
	694 (26.3%)	649 (33.3%)			1.61 (1.31-1.97)	-					
MI						1	345 (13.1%)	201 (10.3%)			
	20.95 [18.93, 23.26]	19.98 [17.92, 22.41]		<0.001	0.91 (0.89-0.93)		518 (19.6%)	366 (18.8%)	<b>⊢</b> •−−1	0.130	1.20 (0.9
coupation							1082 (41%)	731 (37.5%)		0.314	1.12 (0.9
ental work	286 (10.8%)	209 (10.7%)					Total (FT N)			0.014	1.16 (9.9
anual work	1091 (41.3%)	805 (41.3%)		0.925	1.01 (0.83-1.23)	IV.	694 (25.3%)	649 (33.3%)	· · · · · ·	0.001	1.46 (1.1
etired or other	1262 (47.8%)	933 (47.9%)		0.908	1.01 (0.83-1.23)	BMI					
ducation											
rimary education or never attended school	949 (36%)	771 (39.6%)					20.96 [18.93, 23.26]	19.98 [17.92, 22.41]	*	<0.001	0.95 (0.9
econdary education	1352 (51.2%)	907 (46.6%)	H+	0.003	0.83 (0.73-0.94)	Education					
igher education	338 (12.8%)	269 (13.8%)	H	0.828	0.98 (0.81-1.18)	Primary education or never attended school	949 (30%)	771 (39.6%)			
urgery						Primary education or never attended school	848 (3024)	771 (39.0%)			
0	1441 (54.6%)	1198 (61.5%)				Secondary education	1352 (51.2%)	907 (46.6%)	<b>⊢</b> •+1	0.285	0.93 (0.8
8	1198 (45.4%)	749 (38.5%)	H+-1	<0.001	0.75 (0.67-0.85)	Higher education	338 (12.8%)	269 (13.8%)		0.747	1.03 (0.8
hemotherapy						-					
0	1454 (55.1%)	1100 (56.5%)				Surgery					
16	1185 (44.9%)	847 (43.5%)	H+H	0.345	0.94 (0.84-1.06)	No	1441 (54.6%)	1198 (61.5%)			
adiotherapy											
0	2580 (97.8%)	1897 (97.4%) 50 (2.6%)		0.465	1.15 (0.79-1.69)	Yes	1198 (45.4%)	749 (38.5%)	H+	40.001	0.73 (0.6
8 ILS	59 (2.2%)	20 (2.0%)		0.466	1.15 (0.79–1.69)	WL%					
1	877 (33.2%)	541 (27.8%)				eD.	877 (33.2%)	541 (27.8%)			
5	830 (31.5%)	541 (27.8%) 553 (28.4%)		0.320	1.08 (0.93-1.26)						
10	605 (25.2%)	546 (28%)			1.33 (1.14-1.56)	0-5	830 (31.5%)	553 (28.4%)	<b>⊢</b> •−1	0.112	1.14 (0.9
10	267 (10.1%)	307 (15.8%)			1.86 (1.53-2.27)	5-10	665 (25.2%)	546 (28%)		<0.001	1.33 (1.1
GS						>10	267 (10.1%)	307 (15.8%)			1.70 (1.3
= = 18 for women or <28 for men	1138 (43.1%)	1220 (62.7%)				>10	267 (10.1%)	307 (15.8%)		<0.001	1.70 (1.3
18 for women or a28 for men	1501 (56.9%)	727 (37.3%) H	4	<0.001	0.45 (0.40-0.51)	HGS					
esidence						<18 for women or <28 for men	1138 (43.1%)	1220 (62.7%)			
rban	1242 (47.1%)	945 (48.6%)									
ural	1397 (52.9%)	1001 (51.4%)	<b>H</b>	0.007	0.94 (0.84-1.05)	a18 for women or a28 for men	1501 (56.9%)	727 (37.3%)	+	<0.001	0.53 (0.4

(A) Clinical and Nutritional Parameters Related to Increased Fatigue average score (Above the Mean of >24.15) According to Univariable Logistic Regression Analysis. OR, odds ratio; CI, confidence interval; The summary statistics present N% for categorical variables and median [IQR] deviation for continuous variables. (B) Clinical and Nutritional Parameters Related to Increased Fatigue average score (Above the Mean of >24.15) According to Multivariable Logistic Regression Analysis. OR, odds ratio; CI, confidence interval; The summary statistics present N% for categorical variables and median [IQR] deviation for continuous variables.

show a heightened risk of malnutrition in women with cancer (25). Therefore, when formulating nutritional assistance programs, it is crucial to focus on the dietary requirements of female patients.

Malnutrition poses a significant risk to patients with cancer as their nutritional condition can be compromised by both the illness itself and its treatment (26). Understanding the epidemiology of malnutrition could aid in the early management of complications during treatment, potentially improving patient QOL, the intensity of treatment, and outcome (27). Therefore, healthcare professionals should assess the nutritional condition of patients with gastric cancer and offer appropriate interventions or treatments for those suffering from malnutrition.

Individuals diagnosed with stage 4 gastric cancer were more prone to malnutrition, potentially due to interference from the tumor, which obstructs the normal functioning of the pylorus or duodenum and leads to inadequate intake. These patients also experience a surge in metabolic demands, which deteriorates their QOL and physical capacity (28). The results of our analysis are consistent with those reported in previous studies where patients with advanced or uncontrollable stomach cancer often suffer from malnutrition, which can impact their QOL (15). Malnourished patients with a low BMI also had a lower QOL. Previous studies have shown that malnutrition is a poor prognostic factor for many cancers (29). Following gastric cancer surgery, particularly after hospital discharge, malnutrition frequently occurs and can intensify (30). In addition, gastrointestinal malabsorption decreases ingestion of food and weight loss, which are not uncommon sequelae after a gastrectomy, and can lead to malnutrition, which in turn leads to prolonged recovery time, decreased physical function, and decreased QOL (31). Patients with gastric cancer who are undernourished and experience significant WL often report decreased QOL, as we observed in this study. Studies have shown that weight loss can affect cancer mortality and chances of cancer recurrence or secondary cancer formation (32). Nutritional interventions can enhance QOL and survival rates of patients with gastric cancer (32, 33).

The essential steps for preventing and managing malnutrition include early detection and tracking of WL, along with suitable nutritional strategies. The QOL of malnourished patients can be influenced by their geographic location and living conditions. HGS is another indicator of subpar QOL in malnourished patients with gastric cancer. Malnourished patients often experience muscle loss and physical decline, resulting in decreased HGS. Higher HGS is associated with a better physical status, as reported previously (34). A risk factor for cancer is sarcopenia because it increases mortality and postoperative complications and reduces treatment response and QOL (35). For cancer survivors, low HGS is connected with poorer QOL. Enhancing muscle strength should be a key focus to improve QOL of those who have survived cancer (36). Consequently, along with providing proper nutritional assistance, the overall treatment plan must include suitable measures for muscle development and rehabilitation to boost the patient's physical health and overall well-being.

This study had some limitations. Other factors, such as inflammation and body composition, that were not assessed in this study, may impact QOL. We were unable to incorporate these factors into the multivariate analysis as the database we used had

Character	ristics	<appetite (n="2466)&lt;/th" average="" loss="" score=""><th>≥Appetite loss average score (n=2120)</th><th></th><th>P-Value</th><th>OR(95%CI)</th></appetite>	≥Appetite loss average score (n=2120)		P-Value	OR(95%CI)
Sex						
Male Female		1786 (72.4%) 680 (27.6%)	1363 (64.3%) 757 (35.7%)		<0.001	1.53 (1.34–1.75)
Age		660 (27.0%)	/D/ (30.7%)		<0.001	1.53 (1.34-1.75)
Age		60.00 [52.00, 66.00]	60.00 [52.00, 67.00]	•	0.005	1.01 (1.00-1.01)
TNM stag	e					
1		311 (12.6%)	235 (11.1%)			
н		494 (20%)	390 (18.4%)	<b>⊢</b>	0.556	1.07 (0.85-1.35)
ш		1029 (41.7%)	784 (37%)	<b>⊢</b> ↓●──-1	0.513	1.07 (0.87-1.32)
IV		632 (25.6%)	711 (33.5%)	⊢ •	<0.001	1.55 (1.24-1.95)
BMI						
		20.76 [18.73, 23.31]	20.28 [18.08, 22.58]	•	0.001	0.97 (0.95-0.99)
Occupatio						
Mental wor		276 (11.2%)	219 (10.3%)			
Manual wor Retired or o		983 (39.9%) 1207 (48.9%)	913 (43.1%) 988 (46.6%)		0.548	1.08 (0.84-1.37) 0.90 (0.72-1.13)
Education		1207 (40.9%)	300 (40.0%)		0.364	0.90 (0.72-1.13)
	ucation or never attended school	866 (35.1%)	854 (40.3%)			
Secondary		1275 (51.7%)	984 (46.4%)		0.193	0.91 (0.79-1.05)
Higher edu		325 (13.2%)	282 (13.3%)		0.824	0.97 (0.77-1.23)
Surgery						
No		1369 (55.5%)	1270 (59.9%)			
Yes		1097 (44.5%)	850 (40.1%)	<b>→</b> →	<0.001	0.68 (0.56-0.84)
Chemothe	erapy					
No		1351 (54.8%)	1203 (56.7%)			
Yes		1115 (45.2%)	917 (43.3%)	<b>⊢</b> •−−1	0.013	0.79 (0.65-0.95)
Radiother	rapy					
No		2417 (98%)	2060 (97.2%)			
Yes		49 (2%)	60 (2.8%)	<b>⊢</b>	0.831	0.96 (0.63-1.45)
WL%						
⊴0		819 (33.2%)	599 (28.3%)			
0-5		728 (29.5%)	655 (30.9%)		<0.001	1.32 (1.13-1.55)
5-10		637 (25.8%)	574 (27.1%)		0.003	1.29 (1.09-1.52)
>10		282 (11.4%)	292 (13.8%)		<0.001	1.43 (1.16–1.77)
HGS						
	men or <28 for men	1141 (46.3%)	1217 (57.4%)		0.004	0.75 (0.00, 0.05)
≥18 for wor	men or ≥28 for men	1325 (53.7%)	903 (42.6%)		<0.001	0.75 (0.66-0.85)
_				0.5 1 1.5 OR		
B Character Sex	ristics	<appetite (n="2466)&lt;/td" average="" loss="" score=""><td>⊳Appetite loss average score (n=2120)</td><td>0.5 1 1.5 OR</td><td>P-Value</td><td>OR(95%CI)</td></appetite>	⊳Appetite loss average score (n=2120)	0.5 1 1.5 OR	P-Value	OR(95%CI)
Character	ristics	<appetite (n="2466)&lt;br" average="" loss="" score="">1786 (72.4%)</appetite>	≥Appetite loss average score (n=2120) 1363 (64.3%)	0.5 1 1.5 OR	P-Value	OR(95%CI)
Character Sex	ristics			0.5 1 1.5 OR	P–Value ⊲0.001	OR(95%CI) 1.53 (1.34–1.75)
Character Sex Male	ristics	1786 (72.4%)	1363 (64.3%)	0.5 1 1.5 OR		
Character Sex Male Female	rístics	1786 (72.4%)	1363 (64.3%)	0.5 1 1.5 OR		
Character Sex Male Female		1786 (72.4%) 680 (27.6%)	1363 (64.3%) 757 (35.7%)	0.5 1 1.5 OR	<0.001	1.53 (1.34–1.75)
Character Sex Male Female Age		1786 (72.4%) 680 (27.6%) 60.00 (52.00, 66.00) 311 (12.6%)	1363 (64.3%) 757 (35.7%) 60.00 [52.00, 67.00] 235 (11.1%)	0.5 1 1.5 OR	<0.001	1.53 (1.34–1.75) 1.01 (1.00–1.01)
Character Sex Male Female Age TNM stage I		1786 (72.4%) 680 (27.6%) 60.00 (52.00, 66.00) 311 (12.8%) 494 (20%)	1363 (64.3%) 757 (35.7%) 60.00 (52.00, 67.00) 235 (11.1%) 380 (18.4%)	0.5 1 1.5 OR	<0.001 0.005 0.556	1.53 (1.34–1.75) 1.01 (1.00–1.01) 1.07 (0.85–1.35)
Character Sex Male Female Age TNM stage I II		1786 (72.4%) 680 (27.6%) 60.00 (52.00, 66.00) 311 (12.6%) 494 (20%) 1029 (41.7%)	1363 (64.3%) 757 (35.7%) 60.00 (52.00, 67.00) 235 (11.1%) 390 (18.4%) 784 (37%)	0.5 1 1.5 OR	<0.001 0.005 0.556 0.513	1.53 (1.34–1.75) 1.01 (1.00–1.01) 1.07 (0.85–1.35) 1.07 (0.87–1.32)
Character Sex Male Female Age TNM stage I II III		1786 (72.4%) 680 (27.6%) 60.00 (52.00, 66.00) 311 (12.8%) 494 (20%)	1363 (64.3%) 757 (35.7%) 60.00 (52.00, 67.00) 235 (11.1%) 380 (18.4%)	0.5 1 1.5 OR	<0.001 0.005 0.556	1.53 (1.34–1.75) 1.01 (1.00–1.01) 1.07 (0.85–1.35)
Character Sex Male Female Age TNM stage I II		1786 (72.4%) 680 (27.6%) 60.00 (52.00, 66.00) 311 (12.6%) 494 (25%) 1029 (41.7%) 632 (25.6%)	1363 (64.3%) 757 (55.7%) 60.00 (52.00, 67.00) 236 (11.1%) 390 (16.4%) 744 (37%) 711 (33.5%)	0.5 1 1.5 OR	<0.001 0.005 0.556 0.513 <0.001	1.53 (1.34–1.75) 1.01 (1.00–1.01) 1.07 (0.85–1.35) 1.07 (0.87–1.32) 1.55 (1.24–1.95)
Character Sex Male Female Age TNM stag I II II II IV BMI	je	1786 (72.4%) 680 (27.6%) 60.00 (52.00, 66.00) 311 (12.6%) 494 (20%) 1029 (41.7%)	1363 (64.3%) 757 (35.7%) 60.00 (52.00, 67.00) 235 (11.1%) 390 (18.4%) 784 (37%)	0.5 1 1.5 OR	<0.001 0.005 0.556 0.513	1.53 (1.34–1.75) 1.01 (1.00–1.01) 1.07 (0.85–1.35) 1.07 (0.87–1.32)
Character Sex Male Female Age TNM stage I II III	on	1786 (72.4%) 680 (27.6%) 60.00 (52.00, 66.00) 311 (12.6%) 494 (25%) 1029 (41.7%) 632 (25.6%)	1363 (64.3%) 757 (55.7%) 60.00 (52.00, 67.00) 236 (11.1%) 390 (16.4%) 744 (37%) 711 (33.5%)	0.5 1 1.5 OR	<0.001 0.005 0.556 0.513 <0.001	1.53 (1.34–1.75) 1.01 (1.00–1.01) 1.07 (0.85–1.35) 1.07 (0.87–1.32) 1.55 (1.24–1.95)
Character Sex Male Formale Age I I II II IV BMI Occupatic	jë on K	1786 (72.4%) 680 (27.6%) 80.00 (52.00, 66.00) 311 (12.6%) 484 (25%) 1029 (41.7%) 632 (25.6%) 20.76 [18.73, 23.31]	1363 (64.3%) 757 (65.7%) 66.00 (52.00, 67.00) 235 (11.1%) 390 (18.4%) 784 (37%) 711 (33.5%) 20.28 [18.08, 22.58]	0.5 1 1.5 OR	<0.001 0.005 0.556 0.513 <0.001	1.53 (1.34–1.75) 1.01 (1.00–1.01) 1.07 (0.85–1.35) 1.07 (0.87–1.32) 1.55 (1.24–1.95)
Character Sex Male Female Age TNM stage I II III IV BMI Occupatic Mental wor	je on rk	1786 (72.4%) 680 (27.6%) 60.00 (52.00, 66.00) 311 (12.6%) 494 (20%) 1029 (41.7%) 632 (25.6%) 20.76 (18.73, 23.31] 276 (11.2%)	1363 (64.3%) 757 (65.7%) 60.00 (52.00, 67.00) 235 (11.1%) 390 (18.4%) 784 (37%) 711 (33.3%) 20.28 [18.08, 22.58] 219 (10.3%)	0.5 1 1.5 OR	<0.001 0.005 0.556 0.513 <0.001 0.001	1.53 (1.34–1.75) 1.01 (1.00–1.01) 1.07 (0.85–1.35) 1.07 (0.87–1.32) 1.55 (1.24–1.95) 0.97 (0.95–0.99)
Character Sex Mate Female Age TNM stag I II III IV BMI Occupatió Mental wor Manual wor Retired or o Retired or o Education	je on rk rk other n	1786 (72.4%) 680 (27.6%) 60.00 (52.00, 66.00) 311 (12.6%) 404 (25%) 1029 (41.7%) 632 (25.6%) 20.76 [18.73, 23.31] 276 (11.2%) 983 (39.9%) 1207 (48.9%)	1363 (64.3%) 757 (55.7%) 60.00 (52.00, 67.00) 235 (11.1%) 390 (18.4%) 774 (37%) 711 (33.5%) 20.28 [18.08, 22.58] 219 (10.3%) 913 (43.1%) 988 (46.6%)	0.5 1 1.5 OR	<0.001 0.005 0.556 0.513 <0.001 0.001 0.548	1.53 (1.34-1.75) 1.01 (1.00-1.01) 1.07 (0.85-1.35) 1.07 (0.87-1.32) 1.55 (1.24-1.95) 0.97 (0.95-0.99) 1.08 (0.84-1.37)
Character Sex Male Female Age TNM stag I II III IV BMI Occupatic Manual wor Manual wor Manual wor Manual wor Petimary edu	on Ki Ki Ki Ki Subsofor never attended school	1786 (72.4%) 680 (27.6%) 60.00 (52.00, 66.00) 311 (12.6%) 484 (25%) 1029 (41.7%) 632 (25.6%) 20.76 [18.73, 23.31] 276 (11.2%) 983 (39.9%) 1207 (48.9%)	1363 (64.3%) 757 (65.7%) 66.00 (52.00, 67.00) 225 (11.1%) 300 (18.4%) 744 (37%) 711 (33.5%) 20.28 [16.08, 22.58] 219 (10.3%) 913 (43.1%) 988 (46.6%) 854 (40.3%)	0.5 1 1.5 OR	<0.001 0.005 0.556 0.513 <0.001 0.001 0.548	1.53 (1.34-1.75) 1.01 (1.00-1.01) 1.07 (0.85-1.35) 1.07 (0.87-1.32) 1.55 (1.24-1.95) 0.97 (0.95-0.99) 1.08 (0.84-1.37) 0.90 (0.72-1.13)
Character Sex Male Female Age TNM stag I II III IV BMI Occupatić Mental wor Manual wor Retired or o Education Primary od Secondary	on K K K K dem n Aucution or never attended school education	1786 (72.4%) 680 (27.6%) 60.00 (52.00, 66.00) 311 (12.6%) 404 (25%) 1029 (41.7%) 632 (25.6%) 20.76 [18.73, 23.31] 276 (11.2%) 983 (39.9%) 1207 (48.9%)	1363 (64.3%) 757 (55.7%) 60.00 (52.00, 67.00) 235 (11.1%) 390 (18.4%) 774 (37%) 711 (33.5%) 20.28 [18.08, 22.58] 219 (10.3%) 913 (43.1%) 988 (46.6%)	0.5 1 1.5 OR	<0.001 0.005 0.556 0.513 <0.001 0.001 0.548	1.53 (1.34-1.75) 1.01 (1.00-1.01) 1.07 (0.85-1.35) 1.07 (0.85-1.35) 1.55 (1.24-1.95) 0.97 (0.95-0.99) 1.08 (0.84-1.37) 0.90 (0.72-1.13) 0.91 (0.79-1.05)
Character Sex Male Fornale Age TNM stag I II II IV BMI Occupatic Mental wor Manual wor Retired or of Education Primary ed Secondary Higher edu	on K K K K dem n Aucution or never attended school education	1786 (72.4%) 680 (27.6%) 60.00 (52.00, 66.00) 311 (12.6%) 484 (25%) 1029 (41.7%) 632 (25.6%) 20.76 [18.73, 23.31] 276 (11.2%) 983 (39.9%) 1207 (48.9%)	1363 (64.3%) 757 (65.7%) 66.00 (52.00, 67.00) 225 (11.1%) 300 (18.4%) 744 (37%) 711 (33.5%) 20.28 [16.08, 22.58] 219 (10.3%) 913 (43.1%) 988 (46.6%) 854 (40.3%)	0.5 1 1.5 OR	<0.001 0.005 0.556 0.513 	1.53 (1.34-1.75) 1.01 (1.00-1.01) 1.07 (0.85-1.35) 1.07 (0.87-1.32) 1.55 (1.24-1.95) 0.97 (0.95-0.99) 1.08 (0.84-1.37) 0.90 (0.72-1.13)
Character Sex Male Female Age TNM stag I II II II II II II BMI Occupatic Manual wor Manual wor Retired or c Educatior Primary ed Secondary Higher edu	on K K K K dem n Aucution or never attended school education	1786 (72.4%) 680 (27.6%) 60.00 (52.00, 66.00) 311 (12.6%) 484 (25%) 1029 (41.7%) 632 (25.6%) 20.76 [18.73, 23.51] 276 (11.2%) 1207 (48.9%) 1207 (48.9%) 1207 (48.9%) 1257 (51.7%) 325 (13.2%)	1363 (64.3%) 757 (65.7%) 60.00 (52.00, 67.00) 235 (11.1%) 390 (18.4%) 744 (37%) 711 (33.5%) 20.28 (18.08, 22.58) 219 (10.3%) 913 (43.1%) 913 (43.1%) 914 (46.5%) 984 (46.3%) 984 (46.3%)	0.5 1 1.5 OR	<0.001 0.005 0.556 0.513 <0.001 0.001 0.048 0.384 0.193	1.53 (1.34-1.75) 1.01 (1.00-1.01) 1.07 (0.85-1.35) 1.07 (0.85-1.35) 1.55 (1.24-1.95) 0.97 (0.95-0.99) 1.08 (0.84-1.37) 0.90 (0.72-1.13) 0.91 (0.79-1.05)
Character Sex Male Female Age TNM stage I II II II II II IV BMI Occupatic Mental wor Manual wor Manual wor Manual wor Manual wor Retred or C Education Primary edu Secondary Higher edu Surgery No	on K K K K dem n Aucution or never attended school education	1786 (72.4%) 680 (27.6%) 60.00 (52.00, 66.00) 311 (12.6%) 1028 (41.7%) 632 (25.6%) 20.76 (18.73, 23.31] 276 (11.2%) 883 (39.9%) 1207 (48.9%) 1207 (48.9%) 1207 (45.1%) 325 (13.2%)	1363 (64.3%) 757 (65.7%) 60.00 (52.00, 67.00) 235 (11.1%) 784 (37%) 711 (63.5%) 20 28 [18.08, 22.58] 219 (10.3%) 913 (43.1%) 988 (46.6%) 988 (46.4%) 282 (13.3%)	0.5 1 0R 1.5	<0.001 0.005 0.556 0.513 <.0.001 0.001 0.548 0.384 0.183 0.824	1.53 (1.34-1.75) 1.01 (1.00-1.01) 1.07 (0.85-1.35) 1.07 (0.87-1.32) 1.55 (1.24-1.85) 0.97 (0.95-0.99) 1.08 (0.84-1.37) 0.90 (0.72-1.13) 0.91 (0.79-1.05) 0.97 (0.77-1.23)
Character Sex Male Female Age TNM stag I II IV BMI Occupatic Mental wor Manual wor Retired or C Education Primary ed Secondary Higher edu Surgery No	on K K K K K K K K K K K K K	1786 (72.4%) 680 (27.6%) 60.00 (52.00, 66.00) 311 (12.6%) 484 (25%) 1029 (41.7%) 632 (25.6%) 20.76 [18.73, 23.31] 276 (11.2%) 983 (39.9%) 1207 (48.9%) 1207 (48.9%) 1257 (51.7%) 325 (13.2%)	1363 (64.3%) 757 (65.7%) 60.00 (52.00, 67.00) 235 (11.1%) 390 (18.4%) 744 (37%) 711 (33.5%) 20.28 (18.08, 22.58) 219 (10.3%) 913 (43.1%) 913 (43.1%) 914 (46.5%) 984 (46.3%) 984 (46.3%)	0.5 1 1.5 OR	<0.001 0.005 0.556 0.513 <.0.001 0.001 0.548 0.384 0.183 0.824	1.53 (1.34-1.75) 1.01 (1.00-1.01) 1.07 (0.85-1.35) 1.07 (0.85-1.35) 1.55 (1.24-1.95) 0.97 (0.95-0.99) 1.08 (0.84-1.37) 0.90 (0.72-1.13) 0.91 (0.79-1.05)
Character Sex Male Female Age TNM stag I II III IV BMI Occupation Mental work Retired or C Education Primary edu Secondary Higher edu Surgery No Yes C	on K K K K K K K K K K K K K	1786 (72.4%) 680 (27.6%) 60 00 (52.00, 66.00) 311 (12.6%) 484 (25%) 1039 (41.7%) 632 (25.6%) 20.76 [18.73, 23.31] 276 (11.2%) 486 (39.5%) 1275 (51.7%) 323 (13.2%) 1360 (55.5%) 1087 (44.5%)	1363 (64.5%) 757 (65.7%) 60.00 (52.00, 67.00) 235 (11.1%) 300 (18.4%) 744 (37%) 711 (33.5%) 20.28 (18.08, 22.58) 219 (10.3%) 913 (43.1%) 918 (46.0%) 918 (46.0%) 2854 (40.3%) 2854 (40.3%) 2824 (13.3%) 2854 (40.3%) 2855 (40.1%)	0.5 1 0R 1.5	<0.001 0.005 0.556 0.513 <.0.001 0.001 0.548 0.384 0.183 0.824	1.53 (1.34-1.75) 1.01 (1.00-1.01) 1.07 (0.85-1.35) 1.07 (0.87-1.32) 1.55 (1.24-1.85) 0.97 (0.95-0.99) 1.08 (0.84-1.37) 0.90 (0.72-1.13) 0.91 (0.79-1.05) 0.97 (0.77-1.23)
Character Sex Male Female Age I I II II II II II II II II II II II I	on K K K K K K K K K K K K K	1786 (72.4%) 680 (27.6%) 60.00 (52.00, 66.00) 311 (12.6%) 404 (20%) 1029 (41.7%) 632 (25.6%) 20.76 (11.2%) 983 (39.9%) 1207 (48.9%) 866 (35.1%) 1207 (48.9%) 1309 (55.5%) 1097 (44.5%)	1353 (64.3%) 757 (65.7%) 60.00 (52.00, 67.00) 235 (11.1%) 300 (18.4%) 784 (37%) 711 (33.5%) 20128 [18.08, 22.58] 219 (10.3%) 913 (43.1%) 988 (46.6%) 988 (46.4%) 282 (13.3%) 1270 (59.9%) 850 (40.1%)	0.5 1 0R 1.5	<0.001 0.005 0.556 0.513 -0.001 0.001 0.548 0.384 0.384 0.193 0.824 <0.193	1.53 (1.34-1.75) 1.01 (1.00-1.01) 1.07 (0.85-1.35) 1.07 (0.87-1.32) 1.55 (1.24-1.85) 0.97 (0.95-0.99) 1.08 (0.84-1.37) 0.90 (0.72-1.13) 0.91 (0.79-1.05) 0.97 (0.77-1.23) 0.68 (0.56-0.64)
Character Sex Male Fornale Age TNM stage I I II II IV BMI Occupatic Mental wor Manual wor Retired or c Education Primary ed Secondary Higher edu Sugory No Yes Chemother No Yes	e on K K K k k cother n education education education education	1786 (72.4%) 680 (27.6%) 60 00 (52.00, 66.00) 311 (12.6%) 484 (25%) 1039 (41.7%) 632 (25.6%) 20.76 [18.73, 23.31] 276 (11.2%) 486 (39.5%) 1275 (51.7%) 323 (13.2%) 1360 (55.5%) 1087 (44.5%)	1363 (64.5%) 757 (65.7%) 60.00 (52.00, 67.00) 235 (11.1%) 300 (18.4%) 744 (37%) 711 (33.5%) 20.28 (18.08, 22.58) 219 (10.3%) 913 (43.1%) 918 (46.0%) 918 (46.0%) 2854 (40.3%) 2854 (40.3%) 2824 (13.3%) 2854 (40.3%) 2855 (40.1%)	0.5 1 0R 1.5	<0.001 0.005 0.556 0.513 -0.001 0.001 0.548 0.384 0.384 0.193 0.824 <0.193	1.53 (1.34-1.75) 1.01 (1.00-1.01) 1.07 (0.85-1.35) 1.07 (0.87-1.32) 1.55 (1.24-1.85) 0.97 (0.95-0.99) 1.08 (0.84-1.37) 0.90 (0.72-1.13) 0.91 (0.79-1.05) 0.97 (0.77-1.23)
Character Sex Male Female Age TM stage I II II II Metred or C Education Primary edu Secondary Higher edu Surgery No Yes Radiother	e on K K K k k cother n education education education education	1786 (72.4%) 680 (27.6%) 60.00 [52.00, 66.00] 311 (12.6%) 404 (25%) 1020 (41.7%) 632 (25.6%) 20.76 [18.73, 23.31] 276 (11.2%) 883 (39.9%) 1207 (48.9%) 1207 (48.9%) 1309 (55.5%) 1097 (42.5%)	1363 (64.3%) 757 (55.7%) 60.00 [52.00, 67.00] 235 (11.1%) 300 (18.4%) 744 (37%) 711 (33.5%) 20.28 [18.08, 22.58] 219 (10.3%) 913 (43.1%) 918 (46.0%) 918 (46.0%) 282 (13.3%) 2854 (40.3%) 2854 (40.3%) 282 (13.3%) 2854 (40.3%) 2854 (40.3%) 28	0.5 1 0R 1.5	<0.001 0.005 0.556 0.513 -0.001 0.001 0.548 0.384 0.384 0.193 0.824 <0.001	1.53 (1.34-1.75) 1.01 (1.00-1.01) 1.07 (0.85-1.35) 1.07 (0.87-1.32) 1.55 (1.24-1.85) 0.97 (0.95-0.99) 1.08 (0.84-1.37) 0.90 (0.72-1.13) 0.91 (0.79-1.05) 0.97 (0.77-1.23) 0.68 (0.56-0.64)
Character Sex Male Fenale Age TMM stage I I I I I I I I I I I I I I I I I I I	e on K K K k k cother n education education education education	1786 (72.4%) 680 (27.6%) 60.00 (52.00, 66.00) 311 (12.6%) 444 (25%) 1029 (41.7%) 632 (25.6%) 20.76 [18.73, 23.31] 276 (11.2%) 1267 (48.9%) 1267 (48.9%) 1275 (51.7%) 325 (13.2%) 1369 (55.5%) 1369 (55.5%) 1359 (54.8%) 1351 (54.8%) 1351 (54.8%)	1363 (64.3%) 727 (65.7%) 66.00 (52.00, 67.00) 225 (11.1%) 300 (18.4%) 744 (37%) 711 (33.5%) 20.28 [16.08, 22.58] 219 (10.3%) 938 (46.6%) 988 (46.6%) 988 (46.6%) 282 (13.3%) 285 (40.1%) 1270 (59.9%) 355 (40.1%) 1270 (59.9%) 355 (40.1%)	0.5 1 0R 1.5	<0.001 0.005 0.513 	1.53 (1.34-1.75) 1.01 (1.00-1.01) 1.07 (0.85-1.35) 1.07 (0.87-1.32) 1.55 (1.24-1.95) 0.97 (0.95-0.99) 1.06 (0.84-1.37) 0.91 (0.79-1.05) 0.97 (0.77-1.23) 0.68 (0.56-0.84) 0.79 (0.85-0.95)
Character Ser Male Fenale Age Thildson U U U U U U U U U U U U U U U U U U U	e on K K K k k cother n education education education education	1786 (72.4%) 680 (27.6%) 60.00 [52.00, 66.00] 311 (12.6%) 404 (25%) 1020 (41.7%) 632 (25.6%) 20.76 [18.73, 23.31] 276 (11.2%) 883 (39.9%) 1207 (48.9%) 1207 (48.9%) 1309 (55.5%) 1097 (42.5%)	1363 (64.3%) 757 (55.7%) 60.00 [52.00, 67.00] 235 (11.1%) 300 (18.4%) 744 (37%) 711 (33.5%) 20.28 [18.08, 22.58] 219 (10.3%) 913 (43.1%) 918 (46.0%) 918 (46.0%) 282 (13.3%) 2854 (40.3%) 2854 (40.3%) 282 (13.3%) 2854 (40.3%) 2854 (40.3%) 28	0.5 1 0R 1.5	<0.001 0.005 0.556 0.513 -0.001 0.001 0.548 0.384 0.384 0.193 0.824 <0.001	1.53 (1.34-1.75) 1.01 (1.00-1.01) 1.07 (0.85-1.35) 1.07 (0.87-1.32) 1.55 (1.24-1.85) 0.97 (0.95-0.99) 1.08 (0.84-1.37) 0.90 (0.72-1.13) 0.91 (0.79-1.05) 0.97 (0.77-1.23) 0.68 (0.56-0.64)
Character Sex Male Fenale Age TMM stage I I I I I I I I I I I I I I I I I I I	e on K K K k k cother n education education education education	1786 (72.4%) 680 (27.6%) 60.00 (52.00, 66.00) 311 (12.6%) 444 (25%) 1029 (41.7%) 632 (25.6%) 20.76 [18.73, 23.31] 276 (11.2%) 1267 (48.9%) 1267 (48.9%) 1275 (51.7%) 325 (13.2%) 1369 (55.5%) 1369 (55.5%) 1359 (54.8%) 1351 (54.8%) 1351 (54.8%)	1363 (64.3%) 727 (65.7%) 66.00 (52.00, 67.00) 225 (11.1%) 300 (18.4%) 744 (37%) 711 (33.5%) 20.28 [16.08, 22.58] 219 (10.3%) 938 (46.6%) 988 (46.6%) 988 (46.6%) 282 (13.3%) 285 (40.1%) 1270 (59.9%) 355 (40.1%) 1270 (59.9%) 355 (40.1%)	0.5 1 0R 1.5	<0.001 0.005 0.513 	1.53 (1.34-1.75) 1.01 (1.00-1.01) 1.07 (0.85-1.35) 1.07 (0.87-1.32) 1.55 (1.24-1.95) 0.97 (0.95-0.99) 1.06 (0.84-1.37) 0.91 (0.79-1.05) 0.97 (0.77-1.23) 0.68 (0.56-0.84) 0.79 (0.85-0.95)
Character Bac: Mais Fenale Age I I I I I I I I I I I I I I I I I I I	e on K K K k k cother n education education education education	1786 (72.4%) 680 (27.6%) 0.000 (52.00, 66.00) 311 (12.6%) 404 (20%) 1029 (41.7%) 682 (25.0%) 20.76 [18.73, 23.31] 276 (11.2%) 883 (39.9%) 1207 (48.9%) 1207 (48.9%) 1300 (55.5%) 1030 (44.5%) 1351 (54.8%) 1151 (45.2%) 2417 (89%) 49 (2%)	1363 (64.3%) 757 (65.7%) 66.00 (52.00, 67.00) 235 (11.1%) 350 (18.4%) 744 (37%) 711 (33.5%) 20.28 [18.08, 22.58] 219 (10.3%) 983 (46.6%) 983 (46.6%) 988 (46.6%) 988 (46.6%) 282 (13.3%) 1270 (59.9%) 850 (40.1%) 1203 (56.7%) 1203 (56.7%) 1203 (56.7%) 917 (43.5%) 2000 (07.2%) 60 (2.8%)	0.5 1 0R 1.5	<0.001 0.005 0.513 	1.53 (1.34-1.75) 1.01 (1.00-1.01) 1.07 (0.85-1.35) 1.07 (0.87-1.32) 1.55 (1.24-1.95) 0.97 (0.95-0.99) 1.08 (0.84-1.37) 0.99 (0.72-1.13) 0.91 (0.79-1.05) 0.97 (0.77-1.23) 0.68 (0.56-0.84) 0.79 (0.85-0.95) 0.96 (0.63-1.45)
Character Ser. Male Fenale Age Thild stage I I I I I I I I I I I I I I I I I I I	e on K K K k k cother n education education education education	1786 (72.4%) 680 (27.6%) 0.00 (52.00, 66.00) 311 (12.0%) 484 (20%) 1029 (41.7%) 632 (25.6%) 20.76 [18.73, 23.31] 276 (1.2%) 1275 (51.7%) 325 (13.2%) 1369 (55.5%) 1369 (55.5%) 1369 (55.5%) 1351 (54.8%) 1351 (54.8%) 1351 (54.8%) 1351 (54.8%) 2417 (48%) 49 (2%)	1363 (64.3%) 757 (65.7%) 60.00 (52.00, 67.00) 235 (11.1%) 390 (18.4%) 784 (327%) 711 (33.5%) 20 28 (18.0%, 22.58) 219 (10.3%) 913 (43.1%) 988 (46.6%) 282 (13.3%) 886 (40.3%) 282 (13.3%) 282 (13.3%) 1270 (59.9%) 880 (40.1%) 280 (40.1%) 280 (40.1%) 280 (40.1%) 280 (40.5%)	0.5 1 0R 1.5	<0.001 0.005 0.513 -<0.001 0.548 0.884 0.193 0.824 -0.001 0.013 0.013	1.53 (1.34-1.75) 1.01 (1.00-1.01) 1.07 (0.85-1.35) 1.07 (0.87-1.32) 1.55 (1.24-1.95) 0.97 (0.95-0.99) 1.06 (0.84-1.37) 0.91 (0.79-1.05) 0.97 (0.77-1.23) 0.68 (0.56-0.84) 0.79 (0.85-0.95)
Character Bac Fenale ThM stage I I I I I I I I I I I I I I I I I I I	e on K K K k k cother n education education education education	1786 (72.4%) 880 (27.6%) 60 00 (52.00, 66.00) 311 (12.0%) 1032 (41.7%) 632 (25.6%) 20.76 (18.73, 23.31] 276 (11.2%) 883 (39.9%) 1207 (48.9%) 1207 (48.9%) 1300 (55.5%) 1300 (55.5%) 1300 (55.5%) 1307 (44.9%) 1315 (54.8%) 1115 (45.4%) 1115 (45.2%) 2417 (10%) 49 (2%)	1363 (64.5%) 757 (65.7%) 60.00 (52.00, 67.00) 235 (11.1%) 744 (37%) 711 (33.5%) 20.28 (18.08, 22.58) 219 (10.3%) 913 (43.1%) 913 (43.1%) 914 (46.4%) 222 (13.3%) 988 (46.4%) 222 (13.3%) 988 (46.4%) 222 (13.3%) 988 (46.1%) 228 (40.1%) 228 (40.1%) 230 (40.1%) 1203 (56.7%) 917 (43.3%) 917 (43.3%) 917 (43.3%)	0.5 1 0R 1.5	<0.001 0.005 0.559 0.513 0.001 0.001 0.548 0.384 0.384 0.383 0.824 <0.001 0.013 0.831 0.831	1.53 (1.34-1.75) 1.01 (1.00-1.01) 1.07 (0.85-1.35) 1.07 (0.85-1.35) 1.55 (1.24-1.95) 0.97 (0.95-0.99) 1.08 (0.84-1.37) 0.90 (0.72-1.13) 0.91 (0.79-1.65) 0.97 (0.77-1.23) 0.68 (0.55-0.84) 0.79 (0.65-0.95) 0.96 (0.63-1.45) 1.32 (1.13-1.55)
Character Ser. Mala Fenale Age Thild stage II II II II II II II II II II II II II	e on K K K k k cother n education education education education	1786 (72.4%) 680 (27.6%) 0.000 (52.00, 66.00) 311 (12.8%) 484 (25%) 1029 (41.7%) 632 (25.6%) 20.76 [18.73, 23.31] 276 (11.2%) 1267 (48.9%) 1275 (51.7%) 325 (13.2%) 1369 (55.5%) 1077 (44.5%) 1351 (54.8%) 1351 (54.8%) 1351 (54.8%) 1151 (45.2%) 2417 (10%) 49 (23.5%) 257 (25.5%)	1363 (64.3%) 757 (65.7%) 60.00 (52.00, 67.00) 235 (11.1%) 350 (18.4%) 744 (37%) 711 (33.5%) 20.28 [18.08, 22.58] 219 (10.3%) 988 (46.6%) 988 (46.0%) 8854 (40.3%) 988 (46.6%) 282 (13.3%) 282 (13.3%) 283 (40.1%) 1270 (59.9%) 350 (40.1%) 1270 (59.9%) 350 (40.1%) 1270 (59.9%) 350 (40.1%) 1270 (59.9%) 500 (07.2%) 00 (2.8%)	0.5 1 0R 1.5	<0.001 0.005 0.513 -0.001 0.548 0.384 0.193 0.824 -0.001 0.013 0.831 -0.001	1.53 (1.34-1.75) 1.01 (1.00-1.01) 1.07 (0.85-1.35) 1.07 (0.87-1.32) 1.55 (1.24-1.95) 0.97 (0.95-0.99) 1.06 (0.84-1.37) 0.91 (0.79-1.05) 0.97 (0.77-1.23) 0.68 (0.55-0.84) 0.79 (0.65-0.85) 0.96 (0.63-1.45) 1.32 (1.13-1.55) 1.22 (1.10-1.52)
Character Bac Fenale Are I I I I I I I I I I I I I I I I I I I	e on K K K k k cother n education education education education	1786 (72.4%) 680 (27.6%) 0.000 (52.00, 66.00) 311 (12.8%) 484 (25%) 1029 (41.7%) 632 (25.6%) 20.76 [18.73, 23.31] 276 (11.2%) 1267 (48.9%) 1275 (51.7%) 325 (13.2%) 1369 (55.5%) 1077 (44.5%) 1351 (54.8%) 1351 (54.8%) 1351 (54.8%) 1151 (45.2%) 2417 (10%) 49 (23.5%) 257 (25.5%)	1363 (64.3%) 757 (65.7%) 60.00 (52.00, 67.00) 235 (11.1%) 350 (18.4%) 744 (37%) 711 (33.5%) 20.28 [18.08, 22.58] 219 (10.3%) 988 (46.6%) 988 (46.0%) 8854 (40.3%) 988 (46.6%) 282 (13.3%) 282 (13.3%) 283 (40.1%) 1270 (59.9%) 350 (40.1%) 1270 (59.9%) 350 (40.1%) 1270 (59.9%) 350 (40.1%) 1270 (59.9%) 500 (07.2%) 00 (2.8%)	0.5 1 0R 1.5	<0.001 0.005 0.513 0.513 0.513 0.001 0.548 0.384 0.193 0.824 <0.001 0.013 0.013 0.013 0.013 0.013	1.53 (1.34-1.75) 1.07 (0.85-1.35) 1.07 (0.87-1.32) 1.55 (1.24-1.95) 0.97 (0.95-0.99) 1.08 (0.84-1.37) 0.90 (0.72-1.13) 0.91 (0.79-1.05) 0.97 (0.77-1.23) 0.68 (0.56-0.84) 0.79 (0.85-0.85) 1.32 (1.13-1.55) 1.32 (1.13-1.55) 1.43 (1.16-1.77)
Character Ser. Male Fenale Age I I I I I I I I I I I I I I I I I I I	e on K K K K K A Notation or never attended school education cation erapy rapy	1786 (72.4%) 680 (27.6%) 0.000 (52.00, 66.00) 311 (12.6%) 404 (20%) 1029 (41.7%) 6822 (25.0%) 20.76 [18.73, 23.31] 270 (11.2%) 883 (30.9%) 1207 (48.9%) 1207 (48.9%) 1300 (55.5%) 1300 (55.5%) 1351 (54.9%) 1351 (54.9%) 1351 (54.9%) 1351 (54.9%) 1351 (54.9%) 1351 (54.9%) 1351 (55.5%) 1351 (54.9%) 1351 (55.5%) 1351 (55.5%) 2417 (98%) 40 (2%) 728 (0.5%) 728 (0.5%)	1363 (64.3%) 727 (55.7%) 60.00 [52.00, 67.00] 235 (11.1%) 300 (18.4%) 744 (37%) 711 (33.5%) 20.28 [16.08, 22.58] 219 (10.3%) 913 (43.1%) 908 (46.6%) 282 (13.3%) 285 (40.3%) 1270 (56.9%) 285 (40.1%) 1270 (56.9%) 917 (43.3%) 917 (43.3%) 917 (43.3%) 909 (48.3%) 60 (2.5%) 509 (28.3%) 655 (20.9%) 574 (27.1%) 282 (13.5%)	0.5 1 0R 1.5	<0.001 0.005 0.513 0.513 0.513 0.001 0.548 0.384 0.193 0.824 <0.001 0.013 0.013 0.013 0.013 0.013	1.53 (1.34-1.75) 1.01 (1.00-1.01) 1.07 (0.85-1.35) 1.07 (0.87-1.32) 1.55 (1.24-1.95) 0.97 (0.95-0.99) 1.06 (0.84-1.37) 0.91 (0.79-1.05) 0.97 (0.77-1.23) 0.68 (0.55-0.84) 0.79 (0.65-0.85) 0.96 (0.63-1.45) 1.32 (1.13-1.55) 1.22 (1.10-1.52)

(A) Clinical and Nutritional Parameters Related to Increased Appetite loss average score (Above the Mean of >21.56) According to Univariable Logistic Regression Analysis. OR, odds ratio; CI, confidence interval; The summary statistics present N% for categorical variables and median [IQR] deviation for continuous variables. (B) Clinical and Nutritional Parameters Related to Increased Appetite loss average score (Above the Mean of >21.56) According to Multivariable Logistic Regression Analysis. OR, odds ratio; CI, confidence interval; The summary statistics present N% for categorical variables and median of >21.56) According to Multivariable Logistic Regression Analysis. OR, odds ratio; CI, confidence interval; The summary statistics present N% for categorical variables and median [IQR] deviation for continuous variables.

limited data on these parameters. Future studies should consider these variables. Secondly, we do not have survival information for the study population, and unfortunately we cannot compare whether the PG-SGA stage assessment or the PG-SGA numerical score analyzed in this study is more beneficial for the survival of patients with gastric cancer. Moreover, both PG-SGA and EORTC QLQC30 questionnaires are asked by professional investigators to study the population, which may cause the deviation of scores due to personal subjective reasons.

Malnutrition, which impacts functional survival and QOL, is common in patients with cancer (37). Malnutrition has negative impacts on the clinical outcome, prolongs hospital stays, and

	Symptom	≥Average global QOI score (n=2765)	<average (n="1821)&lt;/th" global="" qoi="" score=""><th></th><th></th><th>P-Value</th><th>OR(95%CI)</th></average>			P-Value	OR(95%CI)
	Have no problem eating					1 Value	01(00/00)
	No	1730 (62.6%)	1544 (84.8%)				
	Yes	1035 (37.4%)	277 (15.2%)	H+H		<0.001	0.59 (0.50-0.71)
	Have no appetite	(,					,
	No	2216 (80.1%)	1086 (59.6%)				
	Yes	549 (19.9%)	735 (40.4%)		<b>⊢</b> • – –	<0.001	2.19 (1.88-2.55)
	Nausea						
	No	2457 (88.9%)	1309 (71.9%)				
	Yes	308 (11.1%)	512 (28.1%)		⊢	<0.001	1.61 (1.34-1.95)
	Vomit						
	No	2542 (91.9%)	1395 (76.6%)				
	Yes	223 (8.1%)	426 (23.4%)		<b>⊢</b> →	<0.001	2.22 (1.81-2.73)
	Constipation						
	No	2588 (93.6%)	1551 (85.2%)				
	Yes	177 (6.4%)	270 (14.8%)		⊢	<0.001	2.00 (1.62-2.48)
	Diarrhea						
	No	2656 (96.1%)	1721 (94.5%)				
	Yes	109 (3.9%)	100 (5.5%)	H	•	0.210	1.21 (0.90-1.63)
	Dry mouth						
	No	2598 (94%)	1619 (88.9%)				
	Yes	167 (6%)	202 (11.1%)	ŀ	<b></b>	0.058	1.26 (0.99-1.59)
	Tasteless food						
	No	2650 (95.8%)	1677 (92.1%)				
	Yes	115 (4.2%)	144 (7.9%)	н		0.244	1.18 (0.89–1.57)
	Food smells bad						
	No	2709 (98%)	1755 (96.4%)				
	Yes	56 (2%)	66 (3.6%)		←	0.688	1.09 (0.73-1.62)
	Dysphagia						
	No	2613 (94.5%)	1695 (93.1%)				
	Yes	152 (5.5%)	126 (6.9%)	H	<b>→</b>	0.360	1.13 (0.87–1.47)
	Early satiety						
	No	2367 (85.6%)	1527 (83.9%)				
	Yes	398 (14.4%)	294 (16.1%)	H	<b>◆</b>	0.617	1.05 (0.87-1.25)
	Pain	0000 (70 00/)	1000 (74 00/)				
	No	2209 (79.9%)	1362 (74.8%)			-0.001	1 20 /1 12 1 54)
	Yes	556 (20.1%)	459 (25.2%)			<0.001	1.32 (1.13–1.54)
				0.5 1			
					OR		
FIGURE 5							

Multivariate logistic regression between patients' self-reported PG-SGA symptoms and poor global QOL average score (<82.83) in the past 2 weeks. OR, odds ratio; CI, confidence interval; The summary statistics present N% for categorical variables and median [IQR] deviation for continuous variables.

reduces the QOL for patient (38). Our findings may help to focus on certain factors in malnourished gastric cancer patients, thereby improving their QOL.

# Data availability statement

The original contributions presented in the study are included in the article/Supplementary Material. Further inquiries can be directed to the corresponding author.

# **Ethics statement**

The studies involving human participants were reviewed and approved by Medical Ethical Review Committees and Institutional Review Boards of the participating registered hospitals. The patients/participants provided their written informed consent to participate in this study.

# Author contributions

HZ: Conceptualization, Investigation, Methodology, Software, Validation, Writing – original draft, Writing – review & editing. CL: Conceptualization, Methodology, Writing – original draft. GR: Conceptualization, Software, Writing – review & editing. XZ: Formal analysis, Writing – original draft. YC: Formal analysis, Writing – review & editing. SL: Validation, Writing – original draft. XYL: Investigation, Writing – review & editing. JS: Writing – original draft. XGL: Writing – original draft. SL: Writing – review & editing. HS: Funding acquisition, Supervision, Writing – review & editing.

# Funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This work was supported by the National Key Research and Development Program (2022YFC2009600, 2022YFC2009601), Laboratory for Clinical

Medicine, Capital Medical University (2023-SYJCLC01), National Multidisciplinary Cooperative Diagnosis and Treatment Capacity Project for Major Diseases : Comprehensive Treatment and Management of Critically Ill Elderly Inpatients (No.2019.YLFW) to HS.

# Acknowledgments

We sincerely thank the INSCOC project members for their substantial work on data collection and patient follow-up.

# **Conflict of interest**

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

# Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

# Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fonc.2024.1336859/ full#supplementary-material

# References

1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin.* (2021) 71:209–49. doi: 10.3322/caac.21660

2. Cao W, Chen HD, Yu YW, Li N, Chen WQ. Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020. *Chin Med J (Engl).* (2021) 134:783–91. doi: 10.1097/CM9.00000000001474

3. Machlowska J, Baj J, Sitarz M, Maciejewski R, Sitarz R. Gastric cancer: epidemiology, risk factors, classification, genomic characteristics and treatment strategies. *Int J Mol Sci.* (2020) 21(11):4012. doi: 10.3390/ijms21114012

4. Chia NY, Tan P. Molecular classification of gastric cancer. Ann Oncol. (2016) 27:763–9. doi: 10.1093/annonc/mdw040

5. Schütte K, Schulz C, Middelberg-Bisping K. Impact of gastric cancer treatment on quality of life of patients. *Best Pract Res Clin Gastroenterol.* (2021) 50-51:101727. doi: 10.1016/j.bpg.2021.101727

 Efficace F, Osoba D, Gotay C, Sprangers M, Coens C, Bottomley A. Has the quality of health-related quality of life reporting in cancer clinical trials improved over time? Towards bridging the gap with clinical decision making. *Ann Oncol.* (2007) 18:775–81. doi: 10.1093/annonc/mdl494

7. Kelley AS, Meier DE. Palliative care-a shifting paradigm. N Engl J Med. (2010) 363:781-2. doi: 10.1056/NEJMe1004139

8. Temel JS, Greer JA, Muzikansky A, Gallagher ER, Admane S, Jackson VA, et al. Early palliative care for patients with metastatic non-small-cell lung cancer. *N Engl J Med.* (2010) 363:733–42. doi: 10.1056/NEJMoa1000678

9. Patel JD, Krilov L, Adams S, Aghajanian C, Basch E, Brose MS, et al. Clinical cancer advances 2013: annual report on progress against cancer from the American society of clinical oncology. *J Clin Oncol.* (2014) 32:129–60. doi: 10.1200/JCO.2013.53.7076

10. Jordan K, Aapro M, Kaasa S, Ripamonti CI, Scotté F, Strasser F, et al. European Society for Medical Oncology (ESMO) position paper on supportive and palliative care. *Ann Oncol.* (2018) 29:36–43. doi: 10.1093/annonc/mdx757

11. Lippman SM, Hawk ET. Cancer prevention: from 1727 to milestones of the past 100 years. *Cancer Res.* (2009) 69:5269-84. doi: 10.1158/0008-5472.CAN-09-1750

12. Suarez-Almazor M, Pinnix C, Bhoo-Pathy N, Lu Q, Sedhom R, Parikh RB. Quality of life in cancer care. *Med.* (2021) 2:885–8. doi: 10.1016/j.medj.2021.07.005

13. Lewandowska A, Rudzki G, Lewandowski T, Próchnicki M, Rudzki S, Laskowska B, et al. Quality of life of cancer patients treated with chemotherapy. *Int J Environ Res Public Health*. (2020) 17(19):6938. doi: 10.3390/ijerph17196938

14. Xunlin NG, Lau Y, Klainin-Yobas P. The effectiveness of mindfulness-based interventions among cancer patients and survivors: a systematic review and metaanalysis. *Support Care Cancer*. (2020) 28:1563–78. doi: 10.1007/s00520-019-05219-9

15. Mizukami T, Piao Y. Role of nutritional care and general guidance for patients with advanced or metastatic gastric cancer. *Future Oncol.* (2021) 17:3101–9. doi: 10.2217/fon-2021-0186

16. Bovero A, Leombruni P, Miniotti M, Rocca G, Torta R. Spirituality, quality of life, psychological adjustment in terminal cancer patients in hospice. *Eur J Cancer Care (Engl).* (2016) 25:961–9. doi: 10.1111/ecc.2016.25.issue-6

17. Fu L, Feng X, Jin Y, Lu Z, Li R, Xu W, et al. Symptom clusters and quality of life in gastric cancer patients receiving chemotherapy. *J Pain Symptom Manage*. (2022) 63:230–43. doi: 10.1016/j.jpainsymman.2021.09.003

18. Weir CB, Jan A. *BMI classification percentile and cut off points.* Treasure Island (FL: StatPearls Publishing LLC (2023).

19. Chen LK, Woo J, Assantachai P, Auyeung TW, Chou MY, Iijima K, et al. Asian working group for sarcopenia: 2019 consensus update on sarcopenia diagnosis and treatment. *J Am Med Dir Assoc.* (2020) 21:300–7.e2. doi: 10.1016/j.jamda.2019.12.012

20. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. *J Natl Cancer Inst.* (1993) 85:365–76. doi: 10.1093/jnci/85.5.365

21. Giesinger JM, Kieffer JM, Fayers PM, Groenvold M, Petersen MA, Scott NW, et al. Replication and validation of higher order models demonstrated that a summary score for the EORTC QLQ-C30 is robust. *J Clin Epidemiol.* (2016) 69:79–88. doi: 10.1016/j.jclinepi.2015.08.007

22. Necula L, Matei L, Dragu D, Neagu AI, Mambet C, Nedeianu S, et al. Recent advances in gastric cancer early diagnosis. *World J Gastroenterol.* (2019) 25:2029–44. doi: 10.3748/wjg.v25.i17.2029

23. Pan X, Tao H, Nie M, Liu Y, Huang P, Liu S, et al. A clinical study of traditional Chinese medicine prolonging the survival of advanced gastric cancer patients by regulating the immunosuppressive cell population: A study protocol for a multicenter, randomized controlled trail. *Med (Baltimore)*. (2020) 99:e19757. doi: 10.1097/MD.000000000019757

24. Mahar AL, Coburn NG, Karanicolas PJ, Viola R, Helyer LK. Effective palliation and quality of life outcomes in studies of surgery for advanced, non-curative gastric cancer: a systematic review. *Gastric Cancer*. (2012) 15 Suppl 1:S138–45. doi: 10.1007/ s10120-011-0070-0

25. Guo ZQ, Yu JM, Li W, Fu ZM, Lin Y, Shi YY, et al. Survey and analysis of the nutritional status in hospitalized patients with Malignant gastric tumors and its influence on the quality of life. *Support Care Cancer*. (2020) 28:373–80. doi: 10.1007/s00520-019-04803-3

26. Arends J, Baracos V, Bertz H, Bozzetti F, Calder PC, Deutz NEP, et al. ESPEN expert group recommendations for action against cancer-related malnutrition. *Clin Nutr.* (2017) 36:1187–96. doi: 10.1016/j.clnu.2017.06.017

27. Bossi P, Delrio P, Mascheroni A, Zanetti M. The spectrum of malnutrition/ cachexia/sarcopenia in oncology according to different cancer types and settings: A narrative review. *Nutrients*. (2021) 13(6):1980. doi: 10.3390/nu13061980

28. Troncone E, Fugazza A, Cappello A, Del Vecchio Blanco G, Monteleone G, Repici A, et al. Malignant gastric outlet obstruction: Which is the best therapeutic option? *World J Gastroenterol.* (2020) 26:1847–60. doi: 10.3748/wjg.v26.i16.1847

29. Ma LX, Taylor K, Espin-Garcia O, Anconina R, Suzuki C, Allen MJ, et al. Prognostic significance of nutritional markers in metastatic gastric and esophageal adenocarcinoma. *Cancer Med.* (2021) 10:199–207. doi: 10.1002/cam4.3604

30. Meng Q, Tan S, Jiang Y, Han J, Xi Q, Zhuang Q, et al. Post-discharge oral nutritional supplements with dietary advice in patients at nutritional risk after surgery for gastric cancer: A randomized clinical trial. *Clin Nutr.* (2021) 40:40–6. doi: 10.1016/ j.clnu.2020.04.043

31. Gharagozlian S, Mala T, Brekke HK, Kolbjørnsen LC, Ullerud ÅA, Johnson E. Nutritional status, sarcopenia, gastrointestinal symptoms and quality of life after gastrectomy for cancer - A cross-sectional pilot study. *Clin Nutr ESPEN*. (2020) 37:195–201. doi: 10.1016/j.clnesp.2020.03.001

32. Salas S, Cottet V, Dossus L, Fassier P, Ginhac J, Latino-Martel P, et al. Nutritional Factors during and after Cancer: Impacts on Survival and Quality of Life. *Nutrients*. (2022) 14(14):2958. doi: 10.3390/nu14142958

33. Rinninella E, Cintoni M, Raoul P, Pozzo C, Strippoli A, Bria E, et al. Effects of nutritional interventions on nutritional status in patients with gastric cancer: A systematic review and meta-analysis of randomized controlled trials. *Clin Nutr ESPEN*. (2020) 38:28–42. doi: 10.1016/j.clnesp.2020.05.007

34. Cheung AT, Li WHC, Ho LLK, Xia W, Luo Y, Chan GCF, et al. Associations of physical activity and handgrip strength with different domains of quality of life in pediatric cancer survivors. *Cancers (Basel).* (2022) 14(10):2554. doi: 10.3390/cancers14102554

35. Souza VF, Ribeiro TSC, Marques RA, Petarli GB, Pereira TSS, Rocha JLM, et al. SARC-CalF-assessed risk of sarcopenia and associated factors in cancer patients. *Nutr Hosp.* (2020) 37:1173–8. doi: 10.20960/nh.03158

36. Kim H, Yoo S, Kim H, Park SG, Son M. Cancer survivors with low hand grip strength have decreased quality of life compared with healthy controls: the Korea National Health and nutrition examination survey 2014-2017. *Korean J Fam Med.* (2021) 42:204–11. doi: 10.4082/kjfm.20.0060

37. Xu H, Song C, Yin L, Wang C, Fu Z, Guo Z, et al. Extension protocol for the Investigation on Nutrition Status and Clinical Outcome of Patients with Common Cancers in China (INSCOC) study: 2021 update. *Precis Nutr.* (2022) 1:e00014. doi: 10.1097/PN9.00000000000014

38. Wang L, Cong M, Cui J, Xu H, Chen J, Li T, et al. General rules for treating cancer-related malnutrition. *Precis Nutr.* (2022) 1:e00024. doi: 10.1097/PN9.00000000000024